Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans
复制标题
DOI：
10.1182/blood-2007-01-066522
复制
发表时间：
2007-07-15
期刊：
影响因子：
20.3
通讯作者：
Rosenberg, Amy S.
中科院分区：
文献类型：
--
作者：
Sakamoto, Norihisa;Tsuji, Kazuhide;Rosenberg, Amy S.
最近的研究表明，在异源动物产品中培养的用于治疗目的的细胞群可以获得异种抗原，从而可能限制其用途。在对小鼠胚胎干细胞免疫反应的研究中，我们发现在第二次输注后产生了强烈的抗体反应。来自免疫小鼠的多克隆和单克隆抗体反应均被发现对牛载脂蛋白 B-100 具有特异性，该蛋白与细胞表面丰富的低密度脂蛋白受体结合并被内化。在这里，我们发现，大多数患者使用在含有胎牛血清的培养基中生长的细胞进行 3 种不同类型的基于细胞的治疗，在第二次输注后出现针对牛载脂蛋白 B-100 的抗体反应，并且是主要的特异性。讨论了此类抗体的已知和潜在的临床效果。
Recent studies have demonstrated that cell populations intended for therapeutic purposes that are cultured in heterologous animal products can acquire xenoantigens, potentially limiting their utility. In investigations of the immune response to murine embryonic stem cells, we found that a strong antibody response was generated after the second infusion. Both polyclonal and monoclonal antibody responses, derived from immunized mice, were found to be specific for bovine apolipoprotein B-100, which binds to abundant low-density lipoprotein receptors on the cell surface and is internalized. Here we show that in the majority of patients administered 3 different types of cell-based therapies using cells grown in fetal calf serum-containing media, an antibody response to bovine apolipoprotein B-100 develops after the second infusion and is the dominant specificity. The known and potential clinical effects of such antibodies are discussed.